文献速递慢性肾脏病

奥比他韦/帕利瑞韦/利托那韦治疗HCV基因1或4型合并晚期肾病

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease.
PubMed 文献 · Kidney Int Rep · 2018-10-09

两项3期开放标签多中心研究评估OBV/PTV/r±DSV±RBV治疗HCV基因1或4型合并CKD 4/5期患者的安全性和有效性,66例患者总体SVR12率达95%,包括透析和代偿期肝硬化患者。

要点

  • OBV/PTV/r±DSV±RBV治疗合并晚期肾病的HCV基因1或4型感染SVR12率达95%。
  • 3例因不良事件停药,1例病毒学失败。

核心结论

  • OBV/PTV/r±DSV±RBV耐受性良好,合并CKD 4/5期的HCV基因1或4型患者SVR12率高。

研究设计与样本

  • 两项3期开放标签多中心研究(RUBY-I Cohort 2和RUBY-II)纳入66例CKD 4/5期合并HCV基因1或4型感染患者。
  • RUBY-I Cohort 2:初治或经治GT1a/1b伴或不伴肝硬化,接受OBV/PTV/r+DSV 12周(GT1a肝硬化24周),所有GT1a用RBV。
  • RUBY-II:初治无肝硬化GT1a或GT4,接受12周无RBV方案(GT1a用OBV/PTV/r+DSV;GT4用OBV/PTV/r)。

主要发现

  • 总体SVR12率为95%(63/66),1例病毒学失败。
  • 50例(76%)接受透析,15例(23%)有代偿期肝硬化。
  • 3例因不良事件停药。
  • 无RBV的RUBY-II研究无血红蛋白相关不良事件。

关键数值与推荐

  • 主要终点为治疗后12周持续病毒学应答(SVR12)。

临床怎么用

  • 对于HCV基因1或4型合并CKD 4/5期患者,可考虑OBV/PTV/r±DSV±RBV方案,但含RBV时需密切监测不良事件并及时调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Hepatitis C virus (HCV) infection is common in patients with end-stage renal disease. We investigated the safety and efficacy of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) ± dasabuvir (DSV) ± ribavirin (RBV) in 2 phase 3, open-label, multicenter studies in patients with stage 4 or 5 chronic kidney disease (CKD). METHODS: RUBY-I, Cohort 2 enrolled treatment-naïve or -experienced patients with HCV genotype (GT) 1a or 1b infection, with or without cirrhosis. Patients received 12 weeks (24 weeks for GT1a patients with cirrhosis) of OBV/PTV/r + DSV; all GT1a patients received RBV. RUBY-II enrolled treatment-naïve patients with GT1a or GT4 infection without cirrhosis. All patients received 12 weeks of RBV-free treatment: OBV/PTV/r + DSV for GT1a-infected patients; OBV/PTV/r for GT4-infected patients. The primary endpoint was sustained virologic response at posttreatment week 12 (SVR12). RESULTS: RUBY-I, Cohort 2 and RUBY-II enrolled 66 patients, including 50 (76%) on dialysis; 15 (23%) had compensated cirrhosis. Overall, the SVR12 rate was 95% (63/66); 1 patient had virologic failure. There were 3 discontinuations due to adverse events. Seventy-three percent (27/37) of patients receiving RBV had adverse events leading to RBV dose modification. The RBV-free RUBY-II study had no hemoglobin-associated adverse events. CONCLUSION: Treatment with OBV/PTV/r ± DSV ± RBV was well tolerated and patients with HCV GT1 or 4 infection and stage 4 or 5 CKD had high SVR12 rates, including patients with compensated cirrhosis and/or prior treatment experience.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Lawitz E, Gane E, Cohen E, et al. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease. Kidney Int Rep. 2018. PMID: 30775622. doi:10.1016/j.ekir.2018.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。